HRP20000726B1 - Quinoline derivatives - Google Patents
Quinoline derivativesInfo
- Publication number
- HRP20000726B1 HRP20000726B1 HR20000726A HRP20000726A HRP20000726B1 HR P20000726 B1 HRP20000726 B1 HR P20000726B1 HR 20000726 A HR20000726 A HR 20000726A HR P20000726 A HRP20000726 A HR P20000726A HR P20000726 B1 HRP20000726 B1 HR P20000726B1
- Authority
- HR
- Croatia
- Prior art keywords
- propyl
- iso
- butyl
- ethyl
- quinoline derivatives
- Prior art date
Links
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 2
- -1 methoxy, ethoxy Chemical group 0.000 abstract 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000001246 bromo group Chemical group Br* 0.000 abstract 1
- 150000001767 cationic compounds Chemical class 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 150000002892 organic cations Chemical class 0.000 abstract 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9801474A SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Quinoline Derivatives |
| PCT/SE1999/000676 WO1999055678A1 (en) | 1998-04-27 | 1999-04-26 | Quinoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20000726A2 HRP20000726A2 (en) | 2001-04-30 |
| HRP20000726B1 true HRP20000726B1 (en) | 2009-04-30 |
Family
ID=20411103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20000726A HRP20000726B1 (en) | 1998-04-27 | 2000-10-26 | Quinoline derivatives |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1073639B1 (xx) |
| JP (1) | JP4045069B2 (xx) |
| KR (1) | KR100571534B1 (xx) |
| CN (1) | CN1113057C (xx) |
| AP (1) | AP1293A (xx) |
| AT (1) | ATE228505T1 (xx) |
| AU (1) | AU747550B2 (xx) |
| BR (1) | BR9909925B1 (xx) |
| CA (1) | CA2329788C (xx) |
| CZ (1) | CZ297439B6 (xx) |
| DE (1) | DE69904162T2 (xx) |
| DK (1) | DK1073639T3 (xx) |
| EE (1) | EE04275B1 (xx) |
| ES (1) | ES2188242T3 (xx) |
| HK (1) | HK1036618A1 (xx) |
| HR (1) | HRP20000726B1 (xx) |
| HU (1) | HU227709B1 (xx) |
| ID (1) | ID26277A (xx) |
| IL (2) | IL138160A0 (xx) |
| IS (1) | IS2082B (xx) |
| ME (1) | ME00870B (xx) |
| NO (1) | NO315606B1 (xx) |
| NZ (1) | NZ506641A (xx) |
| OA (1) | OA11547A (xx) |
| PL (1) | PL190441B1 (xx) |
| PT (1) | PT1073639E (xx) |
| RS (1) | RS50029B (xx) |
| RU (1) | RU2197481C2 (xx) |
| SE (1) | SE9801474D0 (xx) |
| TR (1) | TR200003061T2 (xx) |
| UA (1) | UA60354C2 (xx) |
| WO (1) | WO1999055678A1 (xx) |
| ZA (1) | ZA200004601B (xx) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) * | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| KR100908655B1 (ko) | 2002-11-27 | 2009-07-21 | 엘지디스플레이 주식회사 | 데이터 공급시간의 변조방법과 이를 이용한액정표시장치의 구동방법 및 장치 |
| SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
| US7838522B2 (en) | 2004-11-17 | 2010-11-23 | Ares Trading S.A. | Benzothiazole formulations and use thereof |
| BRPI0516383A (pt) | 2004-12-21 | 2008-09-02 | Serono Lab | derivados cìclicos de sulfonil amino e o uso dos mesmos |
| EP1844032B1 (en) | 2005-01-31 | 2011-07-13 | Merck Serono SA | N-hydroxyamide derivatives and use thereof |
| KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 ｊｎｋ 억제제 |
| BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
| JP2009507003A (ja) | 2005-09-01 | 2009-02-19 | アレス トレーディング ソシエテ アノニム | 視神経炎の治療 |
| UA92761C2 (ru) * | 2005-10-19 | 2010-12-10 | Тева Фармасьютикл Индастриз, Лтд. | Кристаллы лаквинимода натрия и способ их изготовления |
| AU2007258366B2 (en) | 2006-06-12 | 2012-10-25 | Active Biotech, Ab | Stable laquinimod preparations |
| SI2234485T1 (sl) | 2007-12-20 | 2014-03-31 | Teva Pharmaceutical Industries Ltd. | Stabilni lakvinimodni pripravki |
| EA021227B1 (ru) * | 2008-09-03 | 2015-05-29 | Тева Фармасьютикал Индастриз Лтд. | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции |
| ES2564931T3 (es) * | 2009-07-30 | 2016-03-30 | Teva Pharmaceutical Industries Ltd. | Tratamiento de enfermedad de Crohn con laquinimod |
| DK2467372T3 (en) * | 2009-08-10 | 2016-08-22 | Teva Pharma | TREATMENT OF BDNF-RELATED DISEASES USING LAQUINIMOD |
| SG183515A1 (en) * | 2010-03-03 | 2012-10-30 | Teva Pharma | Treatment of lupus arthritis using laquinimod |
| PT2542079E (pt) | 2010-03-03 | 2014-07-18 | Teva Pharma | Tratamento da artrite reumatoide com uma combinação de laquinimod e metotrexato |
| PE20130613A1 (es) | 2010-03-03 | 2013-06-23 | Teva Pharma | Tratamiento de lupus nefritis usando laquinimod |
| WO2011116091A1 (en) | 2010-03-17 | 2011-09-22 | Novartis Ag | Dispenser |
| KR20130092558A (ko) | 2010-07-09 | 2013-08-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도 |
| ES2563208T3 (es) * | 2010-07-09 | 2016-03-11 | Active Biotech Ab | Método para fabricar quinolina-3-carboxamidas |
| US20120010239A1 (en) * | 2010-07-09 | 2012-01-12 | Ulf Tomas Fristedt | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
| EP2444086A1 (en) | 2010-10-22 | 2012-04-25 | Almirall, S.A. | Combinations comprising DHODH inhibitors and COX inhibitors |
| US8889627B2 (en) | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| WO2013116657A1 (en) | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
| US9284276B2 (en) | 2012-02-16 | 2016-03-15 | Teva Pharmaceutical Industries, Ltd. | N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| MX2015005632A (es) * | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
| RU2545056C2 (ru) * | 2012-12-10 | 2015-03-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здавоохранения и социального развития Российской Федерации (ГБОУ ВПО ПГФА Минздравсоцразвития России) | Противовоспалительное и анальгетическое средство на основе изопропиламида 1,2-дигидро-1н-2-оксоцинхониновой кислоты |
| AU2014216199A1 (en) * | 2013-02-15 | 2015-09-03 | Teva Pharmaceutical Industries Ltd. | Treatment of progressive forms of multiple sclerosis with laquinimod |
| NZ630427A (en) | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| AU2015253330A1 (en) | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
| KR102533033B1 (ko) | 2014-09-23 | 2023-05-15 | 액티브 바이오테크 에이비 | 다발성 골수종의 치료에 사용하기 위한 퀴놀린 카르복사미드 |
| MX2017006110A (es) | 2014-11-19 | 2017-07-27 | Active Biotech Ab | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. |
| CA3157394A1 (en) | 2019-12-19 | 2021-06-24 | Helena ERIKSSON | Compounds for treatment of eye diseases associated with excessive vascularisation |
| MX2022010327A (es) | 2020-03-03 | 2022-11-09 | Active Biotech Ab | Tasquinimod o una sal farmaceuticamente aceptable del mismo para el uso en una terapia combinada. |
| CA3185531A1 (en) | 2020-07-23 | 2022-01-27 | Rebekka Katharina Marita SCHNEIDER-KRAMANN | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
| US20240091215A1 (en) | 2021-01-18 | 2024-03-21 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
| CA3218977A1 (en) | 2021-05-25 | 2022-12-01 | Hans Wannman | A plurality of tasquinimod particles and use thereof |
| IL309486A (en) | 2021-07-02 | 2024-02-01 | Active Biotech Ab | A pharmacy product containing tesquinimod and a method for evaluating the cleanliness of this product |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0059698A1 (en) * | 1981-03-03 | 1982-09-08 | Ab Leo | Heterocyclic carboxamides, compositions containing such compounds, processes for their preparation and methods of treatment therewith |
| WO1992018483A1 (en) * | 1991-04-22 | 1992-10-29 | Fujisawa Pharmaceutical Co., Ltd. | Quinoline derivatives |
-
1998
- 1998-04-27 SE SE9801474A patent/SE9801474D0/xx unknown
-
1999
- 1999-04-26 PL PL99343420A patent/PL190441B1/pl unknown
- 1999-04-26 CN CN99805581A patent/CN1113057C/zh not_active Expired - Fee Related
- 1999-04-26 DK DK99947036T patent/DK1073639T3/da active
- 1999-04-26 TR TR2000/03061T patent/TR200003061T2/xx unknown
- 1999-04-26 KR KR1020007011944A patent/KR100571534B1/ko not_active IP Right Cessation
- 1999-04-26 NZ NZ506641A patent/NZ506641A/en not_active IP Right Cessation
- 1999-04-26 UA UA2000085078A patent/UA60354C2/uk unknown
- 1999-04-26 BR BRPI9909925-0A patent/BR9909925B1/pt not_active IP Right Cessation
- 1999-04-26 AT AT99947036T patent/ATE228505T1/de active
- 1999-04-26 AP APAP/P/2000/001933A patent/AP1293A/en active
- 1999-04-26 CA CA002329788A patent/CA2329788C/en not_active Expired - Fee Related
- 1999-04-26 ES ES99947036T patent/ES2188242T3/es not_active Expired - Lifetime
- 1999-04-26 JP JP2000545838A patent/JP4045069B2/ja not_active Expired - Lifetime
- 1999-04-26 AU AU43013/99A patent/AU747550B2/en not_active Ceased
- 1999-04-26 EP EP99947036A patent/EP1073639B1/en not_active Expired - Lifetime
- 1999-04-26 IL IL13816099A patent/IL138160A0/xx active IP Right Grant
- 1999-04-26 WO PCT/SE1999/000676 patent/WO1999055678A1/en active IP Right Grant
- 1999-04-26 DE DE69904162T patent/DE69904162T2/de not_active Expired - Lifetime
- 1999-04-26 CZ CZ20003849A patent/CZ297439B6/cs not_active IP Right Cessation
- 1999-04-26 OA OA1200000301A patent/OA11547A/en unknown
- 1999-04-26 HU HU0102084A patent/HU227709B1/hu not_active IP Right Cessation
- 1999-04-26 EE EEP200000613A patent/EE04275B1/xx unknown
- 1999-04-26 ME MEP-2000-612A patent/ME00870B/me unknown
- 1999-04-26 RU RU2000129672/04A patent/RU2197481C2/ru not_active IP Right Cessation
- 1999-04-26 ID IDW20002183A patent/ID26277A/id unknown
- 1999-04-26 PT PT99947036T patent/PT1073639E/pt unknown
- 1999-04-26 RS YUP-612/00A patent/RS50029B/sr unknown
-
2000
- 2000-08-30 IL IL138160A patent/IL138160A/en not_active IP Right Cessation
- 2000-08-31 IS IS5615A patent/IS2082B/is unknown
- 2000-09-01 ZA ZA200004601A patent/ZA200004601B/en unknown
- 2000-10-19 NO NO20005254A patent/NO315606B1/no not_active IP Right Cessation
- 2000-10-26 HR HR20000726A patent/HRP20000726B1/xx not_active IP Right Cessation
-
2001
- 2001-08-07 HK HK01105489A patent/HK1036618A1/xx not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0059698A1 (en) * | 1981-03-03 | 1982-09-08 | Ab Leo | Heterocyclic carboxamides, compositions containing such compounds, processes for their preparation and methods of treatment therewith |
| WO1992018483A1 (en) * | 1991-04-22 | 1992-10-29 | Fujisawa Pharmaceutical Co., Ltd. | Quinoline derivatives |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20000726B1 (en) | Quinoline derivatives | |
| HRP20010039B1 (en) | Quinoline derivatives | |
| CA2236814A1 (en) | Quinoline and quinazoline compounds useful in therapy | |
| NZ518296A (en) | N-phenyl-1,2-dihydro-2-oxo-quinoline-3-carboxamide derivatives and their use in the treatment of breast and prostatic cancer | |
| CA2298033A1 (en) | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | |
| HUP9801900A2 (hu) | 2-Metoxi-benzofenon-származékok, intermedierjeik, előállításuk és alkalmazásuk, hatóanyagként ezeket a vegyületeket tartalmazó fungicid készítmények | |
| CA2205274A1 (en) | Novel 2,3 disubstituted-(5,6)-heteroarylfused-pyrimidine-4-ones | |
| CA2239603A1 (en) | Quinolines and quinazolines useful in therapy | |
| NZ503912A (en) | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists | |
| DK0918776T3 (da) | Totalsyntese af antitumor acylfulvener | |
| ES2122258T3 (es) | 4-azaesteroides 15 sustituidos. | |
| ATE180778T1 (de) | Aryl- und heteroaryl- pyrimidine als herbizide | |
| DK0594263T3 (da) | Mellemprodukter til fremstilling af thioalkylthio-cephalosporinderivater | |
| UA35550C2 (uk) | Похідні урацилу, що проявляють гербіцидну активність | |
| TR200001950T2 (tr) | İkameli 2-benzilamino-2-fenil-asetamid bileşikler. | |
| SE8503415D0 (sv) | Novel isoindolinyl-alkyl-piperazines | |
| NZ326675A (en) | Oxazoline arthropodicides | |
| DK0660822T3 (da) | Cykliske benzylamino-, benzylamido- og benzylimidoderivater som antipsykotiske midler | |
| DK149270C (da) | Analogifremgangsmaade til fremstilling af beta-carbolin-3-carboxylsyrederivater | |
| JPS57163368A (en) | 4-aryloxy-1,2,3,4-tetrahydroisoquinoline and intermediate | |
| DK0623131T3 (da) | Alkylderivater af trazodon med CNS-aktivitet | |
| TR199801366T2 (en) | �zooksasefem t�revleri. | |
| DE69217148D1 (de) | Isoxazole derivate als lichtschutzmittel | |
| JPS5427567A (en) | 4-(indoline-2, 2-(2h)-yl) methyl-7-substituted aminospiro (indoline-2,2-(2h)-1-benzopyran) derivatives | |
| JPS52113989A (en) | 2-hydroxy-thiazolo(b3,2,-b)-s-triazoles and preparation or the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| B1PR | Patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20170327 Year of fee payment: 19 |
|
| PBON | Lapse due to non-payment of renewal fee |
Effective date: 20180426 |